KetamineOne Reports Fiscal Q1 2022 Financials: $2.0 Million In Revenue
KetamineOne Capital (NEO: MEDI) released this morning its financial reports for the fiscal quarter ended October 31, 2021. The firm managed
Read more
KetamineOne Capital
KetamineOne Announces Two Studies Focused On PTSD, Depression
KetamineOne Capital (NEO: MEDI) has officially begun its research programs. The firm this morning announced the inaugural launch of not
Read more
KetamineOne Sees Subsidiary Assist In Ketamine Clinical Trials
Ketamine continues to be a hot topic in terms of clinical trials, with KGK Science, a subsidiary of KetamineOne Capital
Read more
KetamineOne Expands Offerings Of IRP Health With New Partnership
KetamineOne Capital (NEO: MEDI) is evidently looking to expanding its service offerings. The firm this morning revealed that it has
Read more
KetamineOne Adds Two Texas Locations To Clinical Network
KetamineOne Capital (NEO: MEDI) has continued to expand its presence across North America. The firm this morning announced that it
Read more
Cognetivity’s Assessment Tool To Be Deployed At KetamineOne Clinics Across North America
Cognetivity Neurosciences (CSE: CGN) will soon see its cognitive assessment tool for the early detection of changes in cognitive performance
Read more
KetamineOne Expands Veteran Clinics With Four New Locations Across Canada
KetamineOne Capital (NEO: MEDI) is expanding its current offerings for veteran-focused multidisciplinary clinics. The company has added a total of
Read more
Ketamine One: Corporate Overview
KetamineOne Capital Ltd. (NEO: MEDI) is a Vancouver-based wellness company with a focus on becoming the North American leader in
Read more
KetamineOne Brings Scent-Enabled Virtual Reality To Psychedelic Therapy
KetamineOne Capital (NEO: MEDI) appears to be taking a rather novel approach to psychedelic treatments. The firm this morning revealed
Read more
KetamineOne Sees CRO Subsidiary Apply For Controlled Substance Dealers License
KetamineOne Capital (NEO: MEDI) this morning announced that its wholly-owned subsidiary, KGK Science, has hit certain milestones related to expanding
Read more